PetVivo (PETV) 10-Q 7 Feb 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Dec. 31, 2019	Jan. 31, 2020
Document And Entity Information
Entity Registrant Name	PetVivo Holdings, Inc.
Entity Central Index Key	0001512922
Document Type	10-Q
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		22,787,320
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Mar. 31, 2019
Current Assets
Cash and cash equivalents	$ 106,240	$ 6,460
Accounts Receivable	500
Inventory, net	12,495	12,495
Employee advance		2,500
Investments - equity securities receivable	1,500
Prepaid expenses	203,097	34,327
Total Current Assets	323,832	55,782
Property and Equipment:
Property and equipment	149,798	149,802
Less: accumulated depreciation	(125,314)	(112,453)
Total Property and Equipment, net	24,484	37,349
Other Assets:
Trademark and patents-net	197,610	589,817
Operating lease right-of-use asset	105,512
Security deposit	8,201	8,201
Total Other Assets	311,323	598,018
Total Assets	659,639	691,149
Current Liabilities
Accounts payable and accrued expenses	723,680	854,990
Accrued expenses - related party	228,335	576,393
Operating lease liability - short term	24,790
Notes payable and accrued interest		18,831
Notes payable and accrued interest - related party	63,165	85,752
Total Current Liabilities	1,039,970	1,535,966
Other Liabilities:
Convertible notes and accrued interest payable	287,057
Operating lease liability (net of current)	80,722
Total Other Liabilities	367,779
Total Liabilities	1,407,749	1,535,966
Commitments and Contingencies (Note 4)
Stockholders' Equity (Deficit):
Preferred stock, par value $0.001, 20,000,000 shares authorized 0 and 0 shares outstanding at December 31, 2019 and March 31, 2019, respectively
Common stock, par value $0.001, 225,000,000 shares authorized 22,477,320 and 19,867,200 shares outstanding at December 31, 2019 and March 31, 2019, respectively	22,477	22,074
Common stock to be issued	139,891	86,333
Additional Paid-In Capital	53,166,687	51,552,688
Accumulated Deficit	(54,077,165)	(52,505,912)
Total Stockholders' Deficit	(748,110)	(844,817)
Total Liabilities and Stockholders' Deficit	$ 659,639	$ 691,149

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Mar. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	225,000,000	225,000,000
Common stock, shares outstanding	22,477,320	19,867,200

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Revenues	$ 500		$ 500
Cost of Sales - Inventory Write-Down	2,145		5,990
Total Cost of Sales	2,145		5,990
Gross Loss	(1,645)		(5,490)
Operating Expenses:
Sales and Marketing	77,109	1,174	85,087	28,005
Intangible Impairment	28,038		28,038
Research and Development	4,768	55,916	11,900	133,789
General and Administrative:
Depreciation and Amortization	137,725	162,590	422,855	485,331
Other General and Administrative	323,476	339,937	942,725	2,737,171
Total General and Administration	461,201	502,527	1,365,580	3,222,502
Total Operating Expenses	571,116	559,617	1,490,605	3,384,296
Operating Loss	(572,761)	(559,617)	(1,496,095)	(3,384,296)
Other Income (Expense)
Gain on Settlement	29,986		29,986
Gain on Sale of Asset			450
Loss on Debt Extinguishment			(81,738)
Interest Expense	(8,418)	(60,326)	(23,855)	(76,112)
Total Other Income (Expense)	21,568	(60,326)	(75,157)	(76,112)
Net Loss before taxes	(551,193)	(619,943)	(1,571,252)	(3,460,408)
Income Tax Provision
Net Loss	$ (551,193)	$ (619,943)	$ (1,571,252)	$ (3,460,408)
Net Loss Per Share: Basic and Diluted	$ (0.02)	$ (0.03)	$ (0.08)	$ (0.19)
Weighted Average Common Shares Outstanding: Basic and Diluted	22,100,045	18,479,975	20,681,994	18,073,786

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Common Stock to be Issued [Member]	Total
Balance at Mar. 31, 2018	$ 18,279	$ 47,257,557	$ (47,748,154)		$ 608,966	$ 136,648
Balance, shares at Mar. 31, 2018	16,451,168
Common stock issued	$ 1,005	607,961			(608,966)
Common stock issued, shares	904,759
Stock-based compensation		279,312				279,312
Stock-based compensation, shares
Stock granted for debt conversion	$ 95	95,366				95,461
Stock granted for debt conversion, shares	85,916
Common stock issued to replace shares to officer	$ 804	1,445,290				1,446,094
Common stock issued to replace shares to officer, shares	723,047
Net loss			(2,099,585)			(2,099,585)
Balance at Jun. 30, 2018	$ 20,183	49,685,486	(49,847,739)			(142,070)
Balance, shares at Jun. 30, 2018	18,164,890
Balance at Mar. 31, 2018	$ 18,279	47,257,557	(47,748,154)		608,966	136,648
Balance, shares at Mar. 31, 2018	16,451,168
Net loss						(3,460,408)
Balance at Dec. 31, 2018	$ 20,543	50,537,541	(51,208,562)	(177,600)	515,807	(312,271)
Balance, shares at Dec. 31, 2018	18,488,782
Balance at Jun. 30, 2018	$ 20,183	49,685,486	(49,847,739)			(142,070)
Balance, shares at Jun. 30, 2018	18,164,890
Stock-based compensation	$ 27	293,332			26,333	319,692
Stock-based compensation, shares	24,384
Stock granted for debt conversion		19,092				19,092
Stock granted for debt conversion, shares
Common stock sold	$ 308	153,585				153,893
Common stock sold, shares	277,008
Net loss			(740,881)			(740,881)
Balance at Sep. 30, 2018	$ 20,518	50,151,495	(50,588,620)		26,333	(390,274)
Balance, shares at Sep. 30, 2018	18,466,282
Stock-based compensation		249,061			30,000	279,061
Stock-based compensation, shares
Stock granted for debt conversion		47,156			226,002	273,158
Stock granted for debt conversion, shares
Common stock sold	$ 25	89,829			233,472	323,326
Common stock sold, shares	22,500
Common stock returned to Treasury from escrow				(177,600)		(177,600)
Net loss			(619,942)			(619,943)
Balance at Dec. 31, 2018	$ 20,543	50,537,541	(51,208,562)	$ (177,600)	515,807	(312,271)
Balance, shares at Dec. 31, 2018	18,488,782
Balance at Mar. 31, 2019	$ 22,074	51,552,688	(52,505,912)		86,333	(844,817)
Balance, shares at Mar. 31, 2019	19,867,200
Stock-based compensation		157,134			33,667	190,801
Stock-based compensation, shares
Net loss			(500,887)			(500,887)
Balance at Jun. 30, 2019	$ 22,074	51,709,822	(53,006,799)		120,000	(1,154,903)
Balance, shares at Jun. 30, 2019	19,867,200
Balance at Mar. 31, 2019	$ 22,074	51,552,688	(52,505,912)		86,333	$ (844,817)
Balance, shares at Mar. 31, 2019	19,867,200
Common stock issued, shares						2,610,120
Net loss						$ (1,571,252)
Balance at Dec. 31, 2019	$ 22,477	53,166,687	(54,077,165)		139,891	(748,110)
Balance, shares at Dec. 31, 2019	22,477,320
Balance at Jun. 30, 2019	$ 22,074	51,709,822	(53,006,799)		120,000	(1,154,903)
Balance, shares at Jun. 30, 2019	19,867,200
Common stock issued	$ 120	119,880			(120,000)
Common stock issued, shares	77,700
Stock-based compensation		135,278			102,000	237,278
Stock-based compensation, shares	30,300
Stock granted for debt conversion	$ 1,440	536,263				537,703
Stock granted for debt conversion, shares	1,295,866
Common stock sold	$ 400	99,600				100,000
Common stock sold, shares	360,000
Net loss			(519,173)			(519,173)
Balance at Sep. 30, 2019	$ 24,034	52,600,843	(53,525,972)		102,000	(799,095)
Balance, shares at Sep. 30, 2019	21,631,066
Common stock issued	$ 300	101,700			(102,000)
Common stock issued, shares	270,000
Stock-based compensation	$ 100	292,578			70,500	363,178
Stock-based compensation, shares	90,000
Common stock sold	$ 540	134,460			69,391	204,391
Common stock sold, shares	486,000
Adjustment for 9-for-10 reverse stock split	$ (2,497)	2,497
Adjustment for 9-for-10 reverse stock split, shares	254
Warrants sold		34,609				34,609
Net loss			(551,193)			(551,193)
Balance at Dec. 31, 2019	$ 22,477	$ 53,166,687	$ (54,077,165)		$ 139,891	$ (748,110)
Balance, shares at Dec. 31, 2019	22,477,320

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical)	Nov. 22, 2019	Nov. 30, 2019	Dec. 31, 2019
Statement of Stockholders' Equity [Abstract]
Reverse stock split, description	The Company approved and declared a reverse stock split of all its outstanding common stock at a ratio of 9-for-10 shares. Pursuant to this reverse stock split, each ten (10) shares of PetVivo's outstanding common stock, $.001 par value per share, was combined and converted into nine (9) post-split outstanding shares of common stock, $.001 par value per share. This reverse stock split affected all PetVivo shareholders uniformly and accordingly will not alter any shareholder's percentage interest or ownership of PetVivo equity. Through the date of this filing, 254 shares of common stock have been issued due to rounding up of fractional shares.	The Company effected a 9-for-10 reverse split of our authorized and outstanding shares of common stock. Pursuant to this reverse stock split, each ten (10) shares of PetVivo's outstanding common stock, $.001 par value per share, was combined and converted into nine (9) post-split outstanding shares of common stock, $.001 par value per share	9-for-10 reverse stock split

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss For The Period	$ (1,571,252)	$ (3,460,408)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Stock-based compensation	791,256	878,065
Depreciation and Amortization	422,855	485,331
Loss on debt extinguishment	81,738
Intangible impairment	28,038
Common stock issued to replace shares to officer		1,446,094
Common stock issued by Officer on behalf of PetVivo		77,354
Beneficial conversion feature		66,248
Return of escrowed shares to Treasury		(177,600)
Gain on sale of equipment	(450)
Gain on settlement	(29,986)
Changes in Operating Assets and Liabilities
Increase in inventory		(22,608)
Increase in prepaid expenses and employee advances	(166,270)	(10,090)
Decrease (Increase) in receivables	(500)	163
Interest accrued on convertible notes payable	18,537
Interest accrued on notes payable - related party	4,314
Interest accrued on notes payable		8,776
Increase (Decrease) in accounts payable and accrued expenses	(23,471)	209,685
Increase (Decrease) in accrued expenses - related party	30,053	(98,108)
Net Cash Used in Operating Activities	(415,138)	(597,098)
CASH FLOWS FROM INVESTING ACTIVITIES
Decrease in security deposit		1,999
Increase in investments - equity securities receivable	(1,500)
Proceeds from sale of equipment	450
Purchase of equipment	(1,000)	(23,181)
Increase in patents and trademarks	(44,822)	(70,040)
Net Cash Used in Investing Activities	(46,872)	(91,222)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from stock and warrants sale	339,000	390,005
Proceeds from convertible notes	280,000
Proceeds from bridge notes, net of debt discount		209,748
Proceeds from bridge notes - related party, net of debt discount		50,000
Repayments of convertible notes	(11,479)
Repayments of notes payable	(18,831)
Repayments of notes payable - related party	(26,900)	(12,087)
Net Cash Provided by Financing Activities	561,790	637,666
Net Increase (Decrease) in Cash	99,780	(50,654)
Cash at Beginning of Period	6,460	237,335
Cash at End of Period	106,240	186,681
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash Paid During the Period for: Interest	16,338	13,879
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITES
Notes Payable and accrued interest converted into common stock		(154,280)
Notes Payable and accrued interest converted into common stock - related parties		(71,722)
Increase in Debt Discount on Notes Payable		(65,557)
Stock granted for debt conversion	$ 537,703	$ 387,711

Summary of Significant Accounti

Summary of Significant Accounting Policies and Organization	9 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Significant Accounting Policies and Organization	NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (A) Organization and Description The Company is in the business of licensing and commercializing our proprietary medical devices and biomaterials for the treatment of afflictions and diseases in animals, initially for dogs and horses. The Company’s operations are conducted from its headquarter facilities in suburban Minneapolis, Minnesota. (B) Basis of Presentation PetVivo Holdings, Inc. (the “Company”) was incorporated in Nevada under a former name in 2009 and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in Minnesota PetVivo becoming a wholly-owned subsidiary of the Company. In April 2017, the Company acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly-owned subsidiary of the Company. In November 2019, the Company effected a 9-for-10 reverse split of our authorized and outstanding shares of common stock. Pursuant to this reverse stock split, each ten (10) shares of PetVivo’s outstanding common stock, $.001 par value per share, was combined and converted into nine (9) post-split outstanding shares of common stock, $.001 par value per share; 24,974,518 pre-reverse-split shares of common stock were combined during the 9-for-10 reverse split into 22,477,320 shares of post-reverse-split shares of common stock with 254 shares being issued for fractional shares through the date of the balance sheet. Accordingly, all references to number of shares of common stock and per share data have been adjusted retroactively where applicable to account for this reverse split. The accompanying condensed consolidated financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to the rules and regulations of the SEC. Certain information and note disclosures, which are included in annual financial statements, have been omitted pursuant to these rules and regulations. We believe the disclosures made in these interim unaudited financial statements are adequate to make the information not misleading. These interim financial statements at December 31, 2019 and for the three and nine months ended December 31, 2019 and 2018, in the opinion of our management, include all adjustments (consisting of normal recurring entries) necessary to present fairly our financial position, results of operations and cash flows for the periods presented. The results for the three and nine months ended December 31, 2019 are not necessarily indicative of the results to be expected for the year ended March 31, 2020 or for any future period. These unaudited interim financial statements should be read and considered in conjunction with our audited financial statements and the notes thereto for the year ended March 31, 2019, included in our annual report on Form 10-K filed with the SEC. (C) Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its two wholly-owned Minnesota corporations. All intercompany accounts have been eliminated upon consolidation. (D) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of intangible assets and property and equipment, estimate of fair value of share-based payments and derivative instruments and recorded debt discount, valuation of deferred tax assets and valuation of inventory. (E) Cash and Cash Equivalents The Company considers all highly-liquid, temporary cash investments with an original maturity of three months or less to be cash equivalents. At December 31, 2019, the Company had $106,240 in cash and no cash equivalents. At March 31, 2019, the Company had $6,460 in cash and no cash equivalents. (F) Concentration-Risk The Company maintains its cash with various financial institutions, which at times may exceed limits insured by the Federal Deposit Insurance Corporation (FDIC). At December 31, 2019, cash did not exceed the FDIC uninsured balances and management believes the Company is not exposed to any significant credit risk on cash. (G) Property & Equipment Property and equipment are recorded at cost less accumulated depreciation. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method (after taking into account their respective estimated residual values) over the asset’s estimated useful life of (3) years for equipment, (5) years for automobile, and (7) years for furniture and fixtures. (H) Patents and Trademarks The Company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over the lesser of a useful life of 60 months or the life of the patent. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired. (I) Loss Per Share Basic loss per share is computed by dividing net loss by weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. The Company has 5,220,443 warrants outstanding as of December 31, 2019 with varying exercise prices ranging from $3.89 to $.30/share. The weighted average exercise price for these warrants is $.54/share. These warrants are excluded from the weighted average number of shares because they are considered antidilutive. The Company had 2,896,412 warrants outstanding as of December 31, 2018 with varying exercise prices ranging from $3.89 to $.33/share. The weighted average exercise price for these warrants was $.72/share. These warrants are excluded from the weighted average number of shares because they are considered antidilutive. The Company uses the guidance in ASC 260 to determine if-converted loss per share. ASC 260 states that convertible securities should be considered exercised at the later date of the first day of the reporting period’s quarter or the inception date of the debt instrument. Also, the if-converted method shall not be applied for the purposes of computing diluted EPS if the effect would be antidilutive. At December 31, 2019, the Company had $280,000 in convertible notes and $7,057 in accrued interest outstanding, these notes mature in our fiscal quarter ended June 30, 2021; see Note 8 to these financial statements for more information on these convertible notes. If converted, the $287,057 in outstanding convertible notes and accrued interest would convert into 397,464 shares of common stock at a rate of $.72 per share. (J) Revenue Recognition The Company will recognize revenue on arrangements in accordance with FASB ASC No. 606, “Revenue From Contracts With Customers”. Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. The Company adopted the guidance on April 1, 2018 using the cumulative catch-up transition method. This change in accounting did not have any material effect on the Company’s financial statements. (K) Research and Development The Company expenses research and development costs as incurred. (L) Fair Value of Financial Instruments The Company applies the accounting guidance under FASB ASC 820-10, “Fair Value Measurements” The guidance also establishes a fair value hierarchy for measurements of fair value as follows: ● Level 1 - quoted market prices in active markets for identical assets or liabilities. ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of investments – equity securities receivable, notes payable and accrued interest, notes payable and accrued interest - related party, and convertible notes payable. The carrying amount of the Company’s financial instruments approximates their fair value as of December 31, 2019 and March 31, 2019, due to the short-term nature of these instruments and the Company’s borrowing rate of interest. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. The valuation of the Company’s notes recorded at fair value is determined using Level 3 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. The Company measured its investments – equity securities receivable at fair value at December 31, 2019, see Note 5 to the financial statements included in this Form 10-Q. The Company had no assets and liabilities measured at fair value on a recurring basis at December 31, 2019. (M) Stock-Based Compensation - Non-Employees Equity Instruments Issued to Parties Other Than Employees for Acquiring Goods or Services The Company accounts for equity instruments issued to parties other than employees for acquiring goods or services under guidance of Sub-topic 505-50 of the FASB Accounting Standards Codification (“Sub-topic 505-50”). Pursuant to ASC Section 505-50-30, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. If the Company is a newly formed corporation or shares of the Company are thinly traded the use of share prices established in the Company’s most recent private placement memorandum (“PPM”), or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows: ● Expected term of share options and similar instruments: Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and holder’s expected exercise behavior into the fair value (or calculated value) of the instruments. The Company uses historical data to estimate holder’s expected exercise behavior. If the Company is a newly formed corporation or shares of the Company are thinly traded the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. ● Expected volatility of the entity’s shares and the method used to estimate it. Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly-traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. ● Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. ● Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments. Pursuant to Paragraphs 505-50-25-8 and 505-50-25-9, an entity may grant fully vested, non-forfeitable equity instruments that are exercisable by the grantee only after a specified period of time if the terms of the agreement provide for earlier exercisability if the grantee achieves specified performance conditions. Any measured cost of the transaction shall be recognized in the same period(s) and in the same manner as if the entity had paid cash for the goods or services or used cash rebates as a sales discount instead of paying with, or using, the equity instruments. A recognized asset, expense, or sales discount shall not be reversed if a share option and similar instrument that the counterparty has the right to exercise expires unexercised. (N) Income Taxes The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. Deferred tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. As required by ASC Topic 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company applied ASC Topic 740 to all tax positions for which the statute of limitations remained open. As a result of the implementation of ASC Topic 740, the Company did not recognize any change in the liability for unrecognized tax benefits. The Company is not currently under examination by any federal or state jurisdiction. The Company’s policy is to record tax-related interest and penalties as a component of operating expenses. (O) Inventory Inventories are recorded in accordance with ASC 330 and are stated at the lower of cost and net realizable value. We account for inventories using the first in first out (FIFO) methodology and capitalize costs on a project basis as they occur. The current marketed shelf life of our Kush inventory is 2 years. However, management reserves the right to review and adjust this as appropriate. (P) Recently Issued and Adopted Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Topic 842 affects any entity that enters into a lease, with some specified scope exemptions. The guidance in this ASU supersedes Topic 840, Leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use (“ROU”) asset representing its right to use the underlying asset for the lease term. For public companies, the amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted ASU 2016-02 on April 1, 2019. In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments (Subtopic 825) to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information. The amendments in this Update affect all entities that hold financial assets or owe financial liabilities. The amendments are meant to improve financial reporting by providing relevant information about an entity’s equity investments and reducing the number of items that are recognized in other comprehensive income since this Update requires equity securities to be measured at fair value with changes in the fair value recognized through net income. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted ASU 2016-01 on April 1, 2018. In August 2016, the FASB issued ASU No. 2016-15 Statement of Cashflows (Topic 230) to reduce diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The amendments in this Update apply to all entities, including both business entities and not-for-profit entities that are required to present a statement of cash flows under Topic 230. This Update addresses eight specific cash flow issues and their presentations in the statement of cash flows. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company adopted ASU 2016-15 on April 1, 2018. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Going Concern

Going Concern	9 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 2 - GOING CONCERN The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company incurred a net loss of $1,571,252 and had net cash used in operating activities of $415,138 for the nine-month period ending December 31, 2019. Additionally, the Company has an accumulated deficit of $54,077,165, stockholders’ deficit of $748,110, and working capital deficit of $716,138 at December 31, 2019. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months after the date of issuance on these financial statements. In view of these matters, the Company’s ability to continue as a going concern is dependent upon the Company’s ability to achieve a level of profitability and/or to obtain adequate financing through the issuance of debt or equity in order to finance its operations. Management intends to raise additional funds either through a private placement or public offering of its equity securities. Management believes that the actions presently being taken to further implement its business plan will enable the Company to continue as a going concern. While the Company believes in its viability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and raise additional funds. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Inventory

Inventory	9 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventory	NOTE 3 – INVENTORY As of March 31, 2019 and December 31, 2019, respectively, the Company had approximately $78,000 and $56,000 of finished goods inventory; however, reserves of equal amounts for each respective period were taken because of the substantial doubt in the Company’s ability to utilize this inventory to obtain material sales, primarily due to (among other things) the fact the Company has not obtained controlled study data detailing the safe and effective use of Kush™ in dogs and horses. As of March 31, 2019, all of the Company’s finished goods inventory was in quarantine due to a contamination issue. During the nine months ended December 31, 2019, the Company cleared $19,044 in inventory for release to the public and is utilizing the product to gather data and establish strategic partner relationships. Of the $19,044, $13,054 is the value of the product before quarantined that remains reserved for and $5,990 is the expense incurred to clear this product for use during the nine-month period ended December 31, 2019, which has been expensed as incurred through Cost of Goods Sold. The Company may continue to clear the remainder of our inventory during the fiscal year ended March 31, 2020 and capitalize and take a reserve for certain expenses incurred, which are estimated to be approximately $7,000. Total Inventory is broken out as follows: December 31, 2019 March 31, 2019 Finished Goods $ 56,201 $ 77,936 Reserve for Obsolete Inventory (56,201 ) (77,936 ) Work in Process -0- -0- Manufacturing Supplies 3,127 3,127 Raw Materials 9,368 9,368 Total Inventory $ 12,495 $ 12,495

Lease and Commitments

Lease and Commitments	9 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Lease and Commitments	NOTE 4 – LEASE AND COMMITMENTS Rent expense for the three and nine months ended December 31, 2019 was $13,434 and $37,724, respectively. Rent expense for the three and nine months ended December 31, 2018 was $25,807 and $55,020, respectively. On July 2 nd The Company entered into an eighty-four-month lease for 3,577 square feet of newly constructed office, laboratory and warehouse space located in Edina, Minnesota on May 3, 2017. The base rent is $2,078 per month and the Company is responsible for its proportional share of common space expenses, property taxes, and building insurance. This lease is terminable by the landlord if damage causes the property to no longer be utilized as an integrated whole and by the Company if damage causes the facility to be unusable for a period of 45 days. The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of December 31, 2019: Year Ended March 31, 2020 $ 6,234 2021 24,936 2022 24,936 2023 24,936 2024 24,936 Thereafter 2,078 $ 108,056 In compliance with ASC 842 the Company adopted new guidance in relation to lease accounting on April 1, 2019 whereby we recognized operating lease right-to-use assets and corresponding and equal operating lease liabilities for the lease of our facility in Edina, MN. As of December 31, 2019, planned future base rent lease payments total $108,056, which has been discounted to $105,512 using the 52-week treasury bill coupon equivalent discount rate of 2.18% and a present value model. As of December 31, 2019, the Company only had one operating lease so that the remaining lease term and weighted average discount rate are approximately 5 years and 2.18%, respectively. December 31, 2019 Present value of future base rent lease payments $ 105,512 Base rent payments included in prepaid expenses - Present value of future base rent lease payments – net $ 105,512 As of December 31, 2019, the present value of future base rent lease payments – net is classified between current and non-current assets and liabilities as follows: December 31, 2019 Operating lease right-of-use asset $ 105,512 Total operating lease assets 105,512 Operating lease current liability 24,790 Operating lease other liability 80,722 Total operating lease liabilities $ 105,512 Pursuant to a lease wherein our subsidiary, Gel-Del Technologies, Inc., was the lessee until the lease’s termination in 2017, the Company owes approximately $330,000 to the lessor as of December 31, 2019; this amount is included in accounts payable.

Investments - Equity Securities

Investments - Equity Securities	9 Months Ended
	Dec. 31, 2019
Equity Method Investments and Joint Ventures [Abstract]
Investments - Equity Securities	NOTE 5 – INVESTMENTS – EQUITY SECURITIES On June 28, 2019, the Company entered into a purchase agreement with a third-party to purchase 1,500,000 shares of Emerald Organic Products, Inc. (OTC Pink: “EMOR”) common stock for consideration of $1,500. The Company applied guidance from ASU No. 2016-01 Financial Instruments – Overall – Recognition and Measurement of Financial Assets and Financial Liabilities and ASC 820 to arrive at a fair value at December 31, 2019, of $1,500. The Company took into account many factors when determining the stock’s fair value including, but not limited to, the nature and duration of the restriction on the stock, the extent to which potential buyers would be limited by the restriction, and qualitative and quantitative factors specific to both the instrument and the issuer.

Property and Equipment

Property and Equipment	9 Months Ended
	Dec. 31, 2019
Property and Equipment:
Property and Equipment	NOTE 6 – PROPERTY AND EQUIPMENT The components of property and equipment were as follows: December 31, 2019 March 31, 2019 Leasehold improvements $ 4,602 $ 4,602 Furniture and office equipment 10,130 10,130 Production equipment 109,882 108,882 R&D equipment 25,184 26,188 Total, at cost 149,798 149,802 Accumulated depreciation (125,314 ) (112,453 ) Total, net $ 24,484 $ 37,349 During the three and nine months ended December 31, 2019, depreciation expense was $2,438 and $12,861, respectively. During the three and nine months ended December 31, 2018, depreciation expense was $2,148 and $5,974, respectively. During the nine months ended December 31, 2019, we recorded a gain on sale of asset in the amount of $450 wherein we sold an asset that was fully depreciated and originally purchased for $1,004 for $450.

Intangible Assets

Intangible Assets	9 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	NOTE 7 – INTANGIBLE ASSETS The components of intangible assets, all of which are finite-lived, were as follows: December 31, 2019 March 31, 2019 Patents $ 3,828,137 $ 3,820,374 Trademarks 24,098 22,829 Total, at cost 3,852,235 3,843,203 Accumulated Amortization (3,654,625 ) (3,253,386 ) Total, net $ 197,610 $ 589,817 During the three and nine-month periods ended December 31, 2019, amortization expense was $134,283 and $409,994, respectively. During the three and nine-month periods ended December 31, 2018, amortization expense was $160,442 and $479,356, respectively. Also, during the three and nine-month periods ended December 31, 2019, an intangible impairment expense was recognized whereby we wrote down unamortized, previously-capitalized patent costs amounting to $28,038. During the three and nine-month periods ended December 31, 2018, $-0- in intangible impairment expense was recognized.

Convertible Notes

Convertible Notes	9 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Convertible Notes	NOTE 8 – CONVERTIBLE NOTES At December 31, 2019, the Company is obligated for several convertible notes payable in the total amount of $287,057 made up of $280,000 in principal and $7,057 in interest. The Company entered into these convertible notes during the quarter ended June 30, 2019. All of these convertible notes mature during the quarter ended June 30, 2021, two years from their inception dates. These convertible notes accrue interest at a rate of 10%. Accrued interest is due and payable each calendar quarter in cash; during the three and nine months ended December 31, 2019, the Company paid out $-0- and $11,479, respectively, in accrued interest to these convertible note holders. These convertible notes automatically convert into shares of common stock at a rate of $.72 per share at the earlier of the maturity date or an uplist to a national securities exchange (e.g. NASDAQ or New York Stock Exchange) provided that the Company’s stock price is at least $.87 at the time of the uplist. The convertible note holders have the right to convert their outstanding principal and interest into shares of the Company’s common stock at any time during their note’s term at $.72 per share. No note holders have converted their notes through the date of this 10-Q filing. As of December 31, 2019, these convertible notes did not include a beneficial conversion feature.

Notes Payable - Related Party

Notes Payable - Related Party	9 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Notes Payable - Related Party	NOTE 9 – NOTES PAYABLE – RELATED PARTY At December 31, 2019 and March 31, 2019 the Company was obligated for a related party note payable and accrued interest in the total amount of $63,165 and $85,752, respectively; the maturity date of this note is April 30, 2020. The related party note payable terms are accrual of interest at 8% annually with payments of $3,100 per month, which are applied to interest first, then principal. The terms also include a stipulation that if the Company receives additional financing during any 24-month period from the date of the note in the amount greater than $3,500,000, the Company will immediately pay the officer the principal amount of the note along with all interest due.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	9 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	NOTE 10 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES At December 31, 2019 and March 31, 2019, the Company is obligated to pay $723,680 and $854,990, respectively, in accounts payable and accrued expenses. Of the total at December 31, 2019 of $723,680, $484,069 is made up of accounts payable, while the $239,611 in accrued expenses is made up of past employee’s accrued salaries and related payroll taxes payable. Of the total at March 31, 2019 of $854,990, $524,273 is made up of accounts payable, while the $330,717 in accrued expenses is made up of past employee’s accrued salaries and related payroll taxes payable. The Company has not paid the payroll taxes relating to the accrued salaries, consisting primarily of Social Security and Medicare taxes. At December 31, 2019 and March 31, 2019, respectively, we had accrued $22,235 and $21,482 in payroll taxes payable.

Accrued Expenses - Related Part

Accrued Expenses - Related Party	9 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued Expenses - Related Party	NOTE 11 – ACCRUED EXPENSES – RELATED PARTY At December 31, 2019, the Company is obligated to pay $228,335 in accrued expenses due to related parties. Of the total, $22,783 is made up of payroll taxes payable. At March 31, 2019, the Company was obligated to pay $576,393 in accrued expenses due to related parties. Of the total, $89,186 is made up of accounts payable, while $487,207 is made up of accrued salaries and payroll taxes payable.

Common Stock and Warrants

Common Stock and Warrants	9 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Common Stock and Warrants	NOTE 12 - COMMON STOCK AND WARRANTS Common Stock On November 22 nd During the nine months ended December 31, 2019, the Company issued 2,610,120 shares of common stock as follows: i) 347,500 shares to John Lai (CEO, President & Director) pursuant to a Settlement Agreement whereby Mr. Lai agreed to release the Company of all claims through the date of the agreement, September 11, 2019, including accrued compensation he had earned in the amount of $116,000 and hold the shares for a period of at least 3 years; ii) 575,808 shares to Randall Meyer (Director) pursuant to a Settlement Agreement whereby Mr. Meyer agreed to release the Company of all claims through the date of the agreement, September 11, 2019, including accrued compensation he had earned in the amount of $191,936 and hold the shares for a period of at least 3 years; iii) 204,000 shares to John Dolan (Secretary & Director) pursuant to a Settlement Agreement whereby Mr. Dolan agreed to release the Company of all claims through the date of the agreement, September 11, 2019, including accrued compensation he had earned in the amount of $68,000 and hold the shares for a period of at least 3 years; and iv) 168,060 shares to a former employee pursuant to a Settlement Agreement dated August 29, 2019, whereby this individual agreed to release the Company of all claims, including compensation earned in the amount of $80,029; and v) 108,000 shares to a service provider for services provided during the one-year period ended July 13, 2019 and valued at $1.11/share over that period on a pro-rata basis; and vi) 360,000 shares to one shareholder that the Company sold in exchange for $100,000, which equates to a price per share of $.28/share; and vii) 270,000 shares to one service provider for services to be provided during the one-year period ended December 31, 2020 , whereby this service provider agreed to provide video production, investor relations, and promotional services in exchange for 270,000 shares of common stock. The scope of services includes but is not limited to coordinating the airing of 96 commercials nationally on Bloomberg T.V. network and producing 12, monthly, 10-minute interviews; and viii) 486,000 shares to various accredited investors in exchange for $135,000 in cash, which equates to a price per share of $.28/share; and ix) 90,000 shares to service providers for investor relations services to be performed by Barry Kaplan Associates during the six-month period ending in April 2020. The transactions outlined in this Common Stock section enumerated above i through iii yielded a reduction of $375,936 in Accrued Expenses – Related Party that was owed and payable to them arising from services they provided in the past. The settlement of $80,029 explained in number iv above for a former employee’s accrued salary was accounted for as a reduction of Accounts Payable and Accrued Expenses. A loss on extinguishment of debt was recorded in the amount of $81,738 related to the transactions numbered i through iv. Also, on December 9, 2019, the Company entered into an agreement whereby we agreed to issue 150,000 shares of common stock to a service provider, Launchpad IR, at $.42/share for total consideration of $70,500, for investor relations services. These shares remained unissued at the balance sheet date, December 31, 2019. Also, on December 31, 2019, the Company received $104,000 in exchange for 160,000 units, which equates to $.65/unit, whereby a unit is made up of one share of common stock and ½ warrant share wherein the common stock was recorded at its relative fair value of $69,391 and the warrants are described below in this Note 12’s “Warrants” subsection. These shares remained unissued at the balance sheet date, December 31, 2019. On October 31, 2019, the Company’s Board of Directors also approved a compensation plan for John Lai that included his retention of 600,000 escrowed shares that he never returned to the Company’s Treasury. Warrants During the nine months ended December 31, 2019, the Company granted 360,000 warrants to management team members that vest upon achieving certain performance conditions (milestones). These 360,000 warrants were valued using the Black Scholes valuation model at $199,982. On a quarterly basis, the Company evaluates the probability of these certain milestones being reached and recognizes expense relating to these warrants based on that probability and other criteria. As of December 31, 2019, these milestones were not met and were not probable to occur and as a result the Company recognized $-0- in expense related to these 360,000 warrants that may or may not vest pursuant to their respective milestones. During the nine months ended December 31, 2019, the Company granted warrants to purchase a total of 1,734,524 shares of common stock valued using the Black-Scholes model including: i) warrants for 270,000 shares, valued at $119,954, to three new Directors, Messrs. Scott Johnson, Gregory Cash, and James Martin, with 135,000 vested immediately and 135,000 vesting quarterly between August 2020 and May 2021, and exercisable over a five-year term at $.33/share; and ii) warrants for 220,500 shares, valued at $122,489, to John Dolan, whereby 40,500 were granted as a bonus and were vested immediately on the October 31, 2019 grant date, 90,000 that vest upon a performance-based milestone, and 90,000 that vest quarterly over three years starting on October 1, 2019; and whereby all of these warrants are exercisable for a five-year term at $.56/share; and iii) warrants for 540,000 shares, valued at $299,973, to John Lai, whereby 180,000 vest upon performance-based milestones and 360,000 vest quarterly over three years starting on October 1, 2019; and whereby all of these warrants are exercisable for a five-year term at $.56/share; and iv) warrants for 450,000 shares, valued at $249,997, to John Carruth, whereby 90,000 vest upon performance-based milestones and 360,000 vest quarterly over three years starting on October 1, 2019; and whereby all of these warrants are exercisable for a five-year term at $.56/share; and v) warrants for 41,250 shares, valued at $22,915, to David Deming, whereby they vest monthly during the eleven-month period ending August 31, 2020, have a strike price of $.49 and a five-year term; and vi) warrants for 79,397 shares, valued at $38,744, to John Lai, whereby they vested on December 31, 2019, have a strike price of $.50 and a five-year term; and vii) warrants for 15,880 shares, valued at $7,749, the John Dolan, whereby they vested on December 31, 2019, have a strike price of $.50 and a five-year term; and viii) warrants for 80,000 shares, issued as a detachable warrant in purchased units with a relative fair value of $34,609, whereby an accredited investor purchased 160,000 units for $104,000 at a rate of $.65/unit and a unit equates to one share of common stock and one-half warrant, and furthermore where the warrants are exercisable for a term of 3 years, have a strike price of $1.00/share and are vested immediately; and ix) warrants to several directors for service to the Company, issued and vested on December 31, 2019, with a strike price of $.49/share, and exercisable for a five-year term as follows: a) To Gregory Cash, 7,059 warrants, valued at $3,445; and b) To Robert Rudelius, 5,735 warrants, valued at $2,799; and c) To Scott Johnson, 4,852 warrants, valued at $2,368; and d) To Randall Meyer, 4,852 warrants, valued at $2,368; and e) To David Deming, 4,412 warrants, valued at $2,153; and f) To James Martin, 4,412 warrants, valued at $2,153; and g) To Joseph Jasper, 3,528 warrants, valued at $1,722; and h) To David Masters, 2,647 warrants, valued at $1,292. These warrants’ values were arrived at by using the Black-Scholes valuation model with the following assumptions: i) an expected volatility of the Company’s shares on the date of the grants ranging between approximately 313% and 361%, which was arrived at by taking the number of trading days during the year ended on the date of the grant multiplied by the standard deviation of the percentage change in the closing market price on a day-by-day basis; and ii) a risk-free rate identical to the U.S. Treasury 13-week treasury bill rate on the date of the grants between 2.30% and 1.51%. During the nine months ended December 31, 2019, the Company cancelled 333,000 warrants to purchase a total of 333,000 shares of common stock including: i) warrants for 270,000 shares, valued at $300,770 using the Black-Scholes model, $117,144 in expense of which had yet to be taken at the time of cancellation were cancelled pursuant to the terms of such warrants dictating cancellation upon the two-month anniversary of a cease of service; and ii) warrants for 54,000 shares that were never originally valued, were to be vested upon billing from service providers, and were cancelled because those services were never received; and iii) warrants for 9,000 shares, valued at $6,800 using the Black-Scholes model, $6,800 in expense of which had yet to be taken at the time of cancellation were cancelled pursuant to termination of the holder’s service agreement by the Company. A summary of warrant activity for the year ending March 31, 2019 and nine-month period ending December 31, 2019 is as follows: Number of Weighted- Warrants Weighted- Outstanding, March 31, 2018 3,138,046 0.66 2,190,241 0.63 Granted 1,782,478 0.46 Exercised 999,925 0.40 Expired 11,680 0.33 Cancelled 90,000 1.11 Outstanding, March 31, 2019 3,818,919 0.55 3,035,035 0.54 Granted 1,734,524 0.54 Cancelled 333,000 0.48 Outstanding, December 31, 2019 5,220,443 0.54 3,996,828 0.53 At December 31, 2019, the range of warrant prices for shares under warrants and the weighted-average remaining contractual life is as follows: Warrants Outstanding Warrants Exercisable Range of Warrant Number of Weighted- Weighted- Number of Weighted- .30-.50 2,466,025 0.33 5.01 2,473,900 0.33 .51-1.00 2,195,739 0.57 3.24 1,063,249 0.59 1.01-4.00 558,679 1.39 2.65 459,679 1.44 Total 5,220,443 0.54 4.01 3,996,828 0.53 For the nine-month periods ended December 31, 2019 and 2018, the total stock-based compensation on all instruments was $791,257 and $878,065, respectively. It is expected that the Company will recognize expense after December 31, 2019 related to warrants issued, outstanding, and valued using the Black Scholes pricing model as of December 31, 2019 in the amount of approximately $650,000.

Subsequent Events

Subsequent Events	9 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	NOTE 13 – SUBSEQUENT EVENTS In January 2020 the Company issued 150,000 shares pursuant to our agreement with Launchpad IR entered into and accounted for in December of 2019 and 160,000 shares to an accredited investor for purchase of 160,000 units as described in this Form 10-Q’s Note 12’s Common Stock section. In January 2020 the Company issued 63,141 shares of common stock to a former director of the Company pursuant to a cashless conversion provision within the holder’s warrant whereby 168,750 warrants with a strike price of $.30 per share were converted into 63,141 shares of common stock on a cashless basis. On January 31 st

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Organization (Policies)	9 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description	(A) Organization and Description The Company is in the business of licensing and commercializing our proprietary medical devices and biomaterials for the treatment of afflictions and diseases in animals, initially for dogs and horses. The Company’s operations are conducted from its headquarter facilities in suburban Minneapolis, Minnesota.
Basis of Presentation	(B) Basis of Presentation PetVivo Holdings, Inc. (the “Company”) was incorporated in Nevada under a former name in 2009 and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in Minnesota PetVivo becoming a wholly-owned subsidiary of the Company. In April 2017, the Company acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly-owned subsidiary of the Company. In November 2019, the Company effected a 9-for-10 reverse split of our authorized and outstanding shares of common stock. Pursuant to this reverse stock split, each ten (10) shares of PetVivo’s outstanding common stock, $.001 par value per share, was combined and converted into nine (9) post-split outstanding shares of common stock, $.001 par value per share; 24,974,518 pre-reverse-split shares of common stock were combined during the 9-for-10 reverse split into 22,477,320 shares of post-reverse-split shares of common stock with 254 shares being issued for fractional shares through the date of the balance sheet. Accordingly, all references to number of shares of common stock and per share data have been adjusted retroactively where applicable to account for this reverse split. The accompanying condensed consolidated financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to the rules and regulations of the SEC. Certain information and note disclosures, which are included in annual financial statements, have been omitted pursuant to these rules and regulations. We believe the disclosures made in these interim unaudited financial statements are adequate to make the information not misleading. These interim financial statements at December 31, 2019 and for the three and nine months ended December 31, 2019 and 2018, in the opinion of our management, include all adjustments (consisting of normal recurring entries) necessary to present fairly our financial position, results of operations and cash flows for the periods presented. The results for the three and nine months ended December 31, 2019 are not necessarily indicative of the results to be expected for the year ended March 31, 2020 or for any future period. These unaudited interim financial statements should be read and considered in conjunction with our audited financial statements and the notes thereto for the year ended March 31, 2019, included in our annual report on Form 10-K filed with the SEC.
Principles of Consolidation	(C) Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its two wholly-owned Minnesota corporations. All intercompany accounts have been eliminated upon consolidation.
Use of Estimates	(D) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of intangible assets and property and equipment, estimate of fair value of share-based payments and derivative instruments and recorded debt discount, valuation of deferred tax assets and valuation of inventory.
Cash and Cash Equivalents	(E) Cash and Cash Equivalents The Company considers all highly-liquid, temporary cash investments with an original maturity of three months or less to be cash equivalents. At December 31, 2019, the Company had $106,240 in cash and no cash equivalents. At March 31, 2019, the Company had $6,460 in cash and no cash equivalents.
Concentration-Risk	(F) Concentration-Risk The Company maintains its cash with various financial institutions, which at times may exceed limits insured by the Federal Deposit Insurance Corporation (FDIC). At December 31, 2019, cash did not exceed the FDIC uninsured balances and management believes the Company is not exposed to any significant credit risk on cash.
Property & Equipment	(G) Property & Equipment Property and equipment are recorded at cost less accumulated depreciation. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method (after taking into account their respective estimated residual values) over the asset’s estimated useful life of (3) years for equipment, (5) years for automobile, and (7) years for furniture and fixtures.
Patents and Trademarks	(H) Patents and Trademarks The Company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over the lesser of a useful life of 60 months or the life of the patent. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired.
Loss Per Share	(I) Loss Per Share Basic loss per share is computed by dividing net loss by weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. The Company has 5,220,443 warrants outstanding as of December 31, 2019 with varying exercise prices ranging from $3.89 to $.30/share. The weighted average exercise price for these warrants is $.54/share. These warrants are excluded from the weighted average number of shares because they are considered antidilutive. The Company had 2,896,412 warrants outstanding as of December 31, 2018 with varying exercise prices ranging from $3.89 to $.33/share. The weighted average exercise price for these warrants was $.72/share. These warrants are excluded from the weighted average number of shares because they are considered antidilutive. The Company uses the guidance in ASC 260 to determine if-converted loss per share. ASC 260 states that convertible securities should be considered exercised at the later date of the first day of the reporting period’s quarter or the inception date of the debt instrument. Also, the if-converted method shall not be applied for the purposes of computing diluted EPS if the effect would be antidilutive. At December 31, 2019, the Company had $280,000 in convertible notes and $7,057 in accrued interest outstanding, these notes mature in our fiscal quarter ended June 30, 2021; see Note 8 to these financial statements for more information on these convertible notes. If converted, the $287,057 in outstanding convertible notes and accrued interest would convert into 397,464 shares of common stock at a rate of $.72 per share.
Revenue Recognition	(J) Revenue Recognition The Company will recognize revenue on arrangements in accordance with FASB ASC No. 606, “Revenue From Contracts With Customers”. Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. The Company adopted the guidance on April 1, 2018 using the cumulative catch-up transition method. This change in accounting did not have any material effect on the Company’s financial statements.
Research and Development	(K) Research and Development The Company expenses research and development costs as incurred.
Fair Value of Financial Instruments	(L) Fair Value of Financial Instruments The Company applies the accounting guidance under FASB ASC 820-10, “Fair Value Measurements” The guidance also establishes a fair value hierarchy for measurements of fair value as follows: ● Level 1 - quoted market prices in active markets for identical assets or liabilities. ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of investments – equity securities receivable, notes payable and accrued interest, notes payable and accrued interest - related party, and convertible notes payable. The carrying amount of the Company’s financial instruments approximates their fair value as of December 31, 2019 and March 31, 2019, due to the short-term nature of these instruments and the Company’s borrowing rate of interest. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. The valuation of the Company’s notes recorded at fair value is determined using Level 3 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. The Company measured its investments – equity securities receivable at fair value at December 31, 2019, see Note 5 to the financial statements included in this Form 10-Q. The Company had no assets and liabilities measured at fair value on a recurring basis at December 31, 2019.
Stock-Based Compensation - Non-Employees	(M) Stock-Based Compensation - Non-Employees Equity Instruments Issued to Parties Other Than Employees for Acquiring Goods or Services The Company accounts for equity instruments issued to parties other than employees for acquiring goods or services under guidance of Sub-topic 505-50 of the FASB Accounting Standards Codification (“Sub-topic 505-50”). Pursuant to ASC Section 505-50-30, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. If the Company is a newly formed corporation or shares of the Company are thinly traded the use of share prices established in the Company’s most recent private placement memorandum (“PPM”), or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows: ● Expected term of share options and similar instruments: Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and holder’s expected exercise behavior into the fair value (or calculated value) of the instruments. The Company uses historical data to estimate holder’s expected exercise behavior. If the Company is a newly formed corporation or shares of the Company are thinly traded the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. ● Expected volatility of the entity’s shares and the method used to estimate it. Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly-traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. ● Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. ● Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments. Pursuant to Paragraphs 505-50-25-8 and 505-50-25-9, an entity may grant fully vested, non-forfeitable equity instruments that are exercisable by the grantee only after a specified period of time if the terms of the agreement provide for earlier exercisability if the grantee achieves specified performance conditions. Any measured cost of the transaction shall be recognized in the same period(s) and in the same manner as if the entity had paid cash for the goods or services or used cash rebates as a sales discount instead of paying with, or using, the equity instruments. A recognized asset, expense, or sales discount shall not be reversed if a share option and similar instrument that the counterparty has the right to exercise expires unexercised.
Income Taxes	(N) Income Taxes The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. Deferred tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. As required by ASC Topic 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company applied ASC Topic 740 to all tax positions for which the statute of limitations remained open. As a result of the implementation of ASC Topic 740, the Company did not recognize any change in the liability for unrecognized tax benefits. The Company is not currently under examination by any federal or state jurisdiction. The Company’s policy is to record tax-related interest and penalties as a component of operating expenses.
Inventory	(O) Inventory Inventories are recorded in accordance with ASC 330 and are stated at the lower of cost and net realizable value. We account for inventories using the first in first out (FIFO) methodology and capitalize costs on a project basis as they occur. The current marketed shelf life of our Kush inventory is 2 years. However, management reserves the right to review and adjust this as appropriate.
Recently Issued and Adopted Accounting Pronouncements	(P) Recently Issued and Adopted Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Topic 842 affects any entity that enters into a lease, with some specified scope exemptions. The guidance in this ASU supersedes Topic 840, Leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use (“ROU”) asset representing its right to use the underlying asset for the lease term. For public companies, the amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted ASU 2016-02 on April 1, 2019. In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments (Subtopic 825) to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information. The amendments in this Update affect all entities that hold financial assets or owe financial liabilities. The amendments are meant to improve financial reporting by providing relevant information about an entity’s equity investments and reducing the number of items that are recognized in other comprehensive income since this Update requires equity securities to be measured at fair value with changes in the fair value recognized through net income. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted ASU 2016-01 on April 1, 2018. In August 2016, the FASB issued ASU No. 2016-15 Statement of Cashflows (Topic 230) to reduce diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The amendments in this Update apply to all entities, including both business entities and not-for-profit entities that are required to present a statement of cash flows under Topic 230. This Update addresses eight specific cash flow issues and their presentations in the statement of cash flows. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company adopted ASU 2016-15 on April 1, 2018. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Schedule of Inventory	Total Inventory is broken out as follows: December 31, 2019 March 31, 2019 Finished Goods $ 56,201 $ 77,936 Reserve for Obsolete Inventory (56,201 ) (77,936 ) Work in Process -0- -0- Manufacturing Supplies 3,127 3,127 Raw Materials 9,368 9,368 Total Inventory $ 12,495 $ 12,495

Lease and Commitments (Tables)

Lease and Commitments (Tables)	9 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of Maturity Analysis of Operating Lease Liabilities	The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of December 31, 2019: Year Ended March 31, 2020 $ 6,234 2021 24,936 2022 24,936 2023 24,936 2024 24,936 Thereafter 2,078 $ 108,056
Schedule of Future Lease Payments	As of December 31, 2019, the Company only had one operating lease so that the remaining lease term and weighted average discount rate are approximately 5 years and 2.18%, respectively. December 31, 2019 Present value of future base rent lease payments $ 105,512 Base rent payments included in prepaid expenses - Present value of future base rent lease payments – net $ 105,512
Schedule of Present Value of Future Lease Payments Between Current and Non-current Assets and Liabilities	As of December 31, 2019, the present value of future base rent lease payments – net is classified between current and non-current assets and liabilities as follows: December 31, 2019 Operating lease right-of-use asset $ 105,512 Total operating lease assets 105,512 Operating lease current liability 24,790 Operating lease other liability 80,722 Total operating lease liabilities $ 105,512

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Dec. 31, 2019
Property and Equipment:
Schedule of Property and Equipment	The components of property and equipment were as follows: December 31, 2019 March 31, 2019 Leasehold improvements $ 4,602 $ 4,602 Furniture and office equipment 10,130 10,130 Production equipment 109,882 108,882 R&D equipment 25,184 26,188 Total, at cost 149,798 149,802 Accumulated depreciation (125,314 ) (112,453 ) Total, net $ 24,484 $ 37,349

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	The components of intangible assets, all of which are finite-lived, were as follows: December 31, 2019 March 31, 2019 Patents $ 3,828,137 $ 3,820,374 Trademarks 24,098 22,829 Total, at cost 3,852,235 3,843,203 Accumulated Amortization (3,654,625 ) (3,253,386 ) Total, net $ 197,610 $ 589,817

Common Stock and Warrants (Tabl

Common Stock and Warrants (Tables)	9 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Schedule of Warrant Activity	A summary of warrant activity for the year ending March 31, 2019 and nine-month period ending December 31, 2019 is as follows: Number of Weighted- Warrants Weighted- Outstanding, March 31, 2018 3,138,046 0.66 2,190,241 0.63 Granted 1,782,478 0.46 Exercised 999,925 0.40 Expired 11,680 0.33 Cancelled 90,000 1.11 Outstanding, March 31, 2019 3,818,919 0.55 3,035,035 0.54 Granted 1,734,524 0.54 Cancelled 333,000 0.48 Outstanding, December 31, 2019 5,220,443 0.54 3,996,828 0.53
Schedule of Range of Warrant Prices	At December 31, 2019, the range of warrant prices for shares under warrants and the weighted-average remaining contractual life is as follows: Warrants Outstanding Warrants Exercisable Range of Warrant Number of Weighted- Weighted- Number of Weighted- .30-.50 2,466,025 0.33 5.01 2,473,900 0.33 .51-1.00 2,195,739 0.57 3.24 1,063,249 0.59 1.01-4.00 558,679 1.39 2.65 459,679 1.44 Total 5,220,443 0.54 4.01 3,996,828 0.53

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Organization (Details Narrative) - USD ($)	Nov. 22, 2019	Nov. 30, 2019	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2019
Reverse stock split, description	The Company approved and declared a reverse stock split of all its outstanding common stock at a ratio of 9-for-10 shares. Pursuant to this reverse stock split, each ten (10) shares of PetVivo's outstanding common stock, $.001 par value per share, was combined and converted into nine (9) post-split outstanding shares of common stock, $.001 par value per share. This reverse stock split affected all PetVivo shareholders uniformly and accordingly will not alter any shareholder's percentage interest or ownership of PetVivo equity. Through the date of this filing, 254 shares of common stock have been issued due to rounding up of fractional shares.	The Company effected a 9-for-10 reverse split of our authorized and outstanding shares of common stock. Pursuant to this reverse stock split, each ten (10) shares of PetVivo's outstanding common stock, $.001 par value per share, was combined and converted into nine (9) post-split outstanding shares of common stock, $.001 par value per share	9-for-10 reverse stock split
Common stock, shares outstanding			22,477,320	22,477,320		19,867,200
Fractional shares issued due to reverse stock split		254
Cash			$ 106,240	$ 106,240		$ 6,460
Cash equivalents
Debt instrument maturity date				Apr. 30, 2020
Assets and liabilities measured at fair value
Income tax likelihood percentage				Greater than 50 percent
Inventory terms				2 years
Convertible Notes [Member]
Convertible notes outstanding			280,000	$ 280,000
Accrued interest			$ 7,057	$ 7,057
Debt instrument maturity date				Jun. 30, 2021
Conversion of debt into common stock amount				$ 287,057
Conversion of debt into common stock shares				397,464
Conversion price per share			$ 0.72	$ 0.72
Warrant [Member]
Warrants outstanding				5,220,443	2,896,412
Weighted average, exercise price				$ 0.54	$ 0.72
Warrant [Member] | Maximum [Member]
Warrant exercise price			3.89	3.89	3.89
Warrant [Member] | Minimum [Member]
Warrant exercise price			$ 0.30	$ 0.30	$ 0.33
Patents and Trademarks [Member]
Estimated useful life of intangible asset				60 months
Equipment [Member]
Estimated useful life of assets				3 years
Automobile [Member]
Estimated useful life of assets				5 years
Furniture and Fixtures [Member]
Estimated useful life of assets				7 years
Pre-Reverse Split [Member]
Common stock, shares outstanding		24,974,518

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ (551,193)	$ (519,173)	$ (500,887)	$ (619,943)	$ (740,881)	$ (2,099,585)	$ (1,571,252)	$ (3,460,408)
Net cash used in operating activities							(415,138)	(597,098)
Accumulated deficit	(54,077,165)						(54,077,165)		$ (52,505,912)
Stockholders' deficit	(748,110)	$ (799,095)	$ (1,154,903)	$ (312,271)	$ (390,274)	$ (142,070)	(748,110)	$ (312,271)	$ (844,817)	$ 136,648
Working capital deficit	$ (716,138)						$ (716,138)

Inventory (Details Narrative)

Inventory (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2020	Mar. 31, 2019
Finished goods inventory	$ 56,201		$ 56,201			$ 77,936
Inventory	12,495		12,495			12,495
Inventory reserve	56,201		56,201			77,936
Expenses on costs of goods sold	2,145		5,990
Forecast [Member]
Inventory reserve					$ 7,000
Strategic Partner Relationships [Member]
Inventory	19,044		19,044
Inventory reserve	13,054		13,054
Expenses on costs of goods sold			5,990
Inventory [Member]
Finished goods inventory	$ 56,000		$ 56,000			$ 78,000

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Dec. 31, 2019	Mar. 31, 2019
Inventory Disclosure [Abstract]
Finished Goods	$ 56,201	$ 77,936
Reserve for Obsolete Inventory	(56,201)	(77,936)
Work in Process	0	0
Manufacturing Supplies	3,127	3,127
Raw Materials	9,368	9,368
Total Inventory	$ 12,495	$ 12,495

Lease and Commitments (Details

Lease and Commitments (Details Narrative)	Jul. 13, 2018ft²	Jul. 02, 2018USD ($)	May 03, 2017USD ($)ft²	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2019USD ($)Integer	Dec. 31, 2018USD ($)
Rent expense			$ 2,078	$ 13,434	$ 25,807	$ 37,724	$ 55,020
Labour costs		$ 2,000
Agreement term	1 year		7 years 4 days
Area of land | ft²	1,000		3,577
Operating lease payment				108,056		108,056
Operating lease liability net of discount				$ 105,512		$ 105,512
Operating lease discount rate				2.18%		2.18%
Number of operating lease | Integer						1
Weighted average remaining lease term				5 years		5 years
Weighted average discount rate				2.18%		2.18%
Gel-Del Technologies, Inc [Member]
Operating lease payment				$ 330,000		$ 330,000

Lease and Commitments - Schedul

Lease and Commitments - Schedule of Maturity Analysis of Operating Lease Liabilities (Details)	Dec. 31, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
2020	$ 6,234
2021	24,936
2022	24,936
2023	24,936
2024	24,936
Thereafter	2,078
Total	$ 108,056

Lease and Commitments - Sched_2

Lease and Commitments - Schedule of Future Lease Payments (Details)	Dec. 31, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
Present value of future base rent lease payments	$ 105,512
Base rent payments included in prepaid expenses
Present value of future base rent lease payments - net	$ 105,512

Lease and Commitments - Sched_3

Lease and Commitments - Schedule of Present Value of Future Lease Payments Between Current and Non-current Assets and Liabilities (Details) - USD ($)	Dec. 31, 2019	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Operating lease right-of-use asset	$ 105,512
Total operating lease assets	105,512
Operating lease current liability	24,790
Operating lease other liability	80,722
Total operating lease liabilities	$ 105,512

Investments - Equity Securiti_2

Investments - Equity Securities (Details Narrative) - Purchase Agreement [Member] - Emerald Organic Products Inc [Member] - USD ($)	Jun. 28, 2019	Dec. 31, 2019
Number of shares purchased for acquisition	1,500,000
Value of shares purchased for acquisition	$ 1,500
Fair value of investments		$ 1,500

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Property and Equipment:
Depreciation expense	$ 2,438	$ 2,148	$ 12,861	$ 5,974
Gain on sale of asset			$ 450
Purchase price of assets before depreciation	$ 1,004

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2019	Mar. 31, 2019
Total, at cost	$ 149,798	$ 149,802
Accumulated depreciation	(125,314)	(112,453)
Total, net	24,484	37,349
Leasehold Improvements [Member]
Total, at cost	4,602	4,602
Furniture and Office Equipment [Member]
Total, at cost	10,130	10,130
Production Equipment [Member]
Total, at cost	109,882	108,882
R&D Equipment [Member]
Total, at cost	$ 25,184	$ 26,188

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 134,283	$ 160,442	$ 409,994	$ 479,356
Intangible impairment expense	$ 28,038		$ 28,038

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)	Dec. 31, 2019	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 3,828,137	$ 3,820,374
Trademarks	24,098	22,829
Total, at cost	3,852,235	3,843,203
Accumulated Amortization	(3,654,625)	(3,253,386)
Total, net	$ 197,610	$ 589,817

Convertible Notes (Details Narr

Convertible Notes (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Dec. 31, 2019	Dec. 31, 2019	Mar. 31, 2019
Convertible notes and accrued interest payable	$ 287,057	$ 287,057
Convertible notes maturity date		Apr. 30, 2020
Convertible notes accrued interest rate			8.00%
Convertible Notes Payable [Member]
Convertible notes payable	280,000	$ 280,000
Accrued interest	$ 0	$ 11,479
Convertible notes maturity date		Jun. 30, 2021
Convertible notes accrued interest rate	10.00%	10.00%
Conversion price per share description		These convertible notes automatically convert into shares of common stock at a rate of $.72 per share at the earlier of the maturity date or an uplist to a national securities exchange (e.g. NASDAQ or New York Stock Exchange) provided that the Company's stock price is at least $.87 at the time of the uplist. The convertible note holders have the right to convert their outstanding principal and interest into shares of the Company's common stock at any time during their note's term at $.72 per share.
Conversion price per share	$ 0.72	$ 0.72
Stock price	$ 0.87	$ 0.87
Several Convertible Notes Payable [Member]
Accrued interest		$ 7,057

Notes Payable - Related Party (

Notes Payable - Related Party (Details Narrative) - USD ($)	9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2019
Notes payable and accrued interest	$ 63,165		$ 85,752
Debt instrument maturity date	Apr. 30, 2020
Interest rate			8.00%
Annual monthly payments	$ 3,100
Debt term	24 months
Proceeds from related party debt		$ 50,000
Minimum [Member]
Proceeds from related party debt	$ 3,500,000

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Details Narrative) - USD ($)	Dec. 31, 2019	Mar. 31, 2019
Payables and Accruals [Abstract]
Accounts payable and accrued expenses	$ 723,680	$ 854,990
Accounts payable	484,069	524,273
Accrued salaries and related payroll taxes payable	239,611	330,717
Accrued liabilities	$ 22,235	$ 21,482

Accrued Expenses - Related Pa_2

Accrued Expenses - Related Party (Details Narrative) - USD ($)	Dec. 31, 2019	Mar. 31, 2019
Accrued salaries and payroll taxes payable	$ 239,611	$ 330,717
Accounts payable	484,069	524,273
Related Party [Member]
Accrued expenses, related party	228,335	576,393
Accrued salaries and payroll taxes payable	22,783	487,207
Accounts payable		$ 89,186

Common Stock and Warrants (Deta

Common Stock and Warrants (Details Narrative)	Dec. 09, 2019USD ($)$ / sharesshares	Nov. 22, 2019	Oct. 31, 2019shares	Jul. 13, 2019$ / sharesshares	Nov. 30, 2019	Dec. 31, 2019USD ($)$ / sharesshares	Sep. 30, 2019USD ($)shares	Jun. 30, 2019USD ($)shares	Dec. 31, 2018USD ($)$ / sharesshares	Sep. 30, 2018USD ($)shares	Jun. 30, 2018USD ($)shares	Apr. 30, 2020shares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / shares	Dec. 31, 2019USD ($)$ / sharesshares	Mar. 31, 2019shares
Equity, reverse stock split, description		The Company approved and declared a reverse stock split of all its outstanding common stock at a ratio of 9-for-10 shares. Pursuant to this reverse stock split, each ten (10) shares of PetVivo's outstanding common stock, $.001 par value per share, was combined and converted into nine (9) post-split outstanding shares of common stock, $.001 par value per share. This reverse stock split affected all PetVivo shareholders uniformly and accordingly will not alter any shareholder's percentage interest or ownership of PetVivo equity. Through the date of this filing, 254 shares of common stock have been issued due to rounding up of fractional shares.			The Company effected a 9-for-10 reverse split of our authorized and outstanding shares of common stock. Pursuant to this reverse stock split, each ten (10) shares of PetVivo's outstanding common stock, $.001 par value per share, was combined and converted into nine (9) post-split outstanding shares of common stock, $.001 par value per share	9-for-10 reverse stock split
Number of shares issued														2,610,120
Number of shaes issued for compensaton, value | $						$ 363,178	$ 237,278	$ 190,801	$ 279,061	$ 319,692	$ 279,312
Number of shares issued for services				108,000
Shares issued price per share | $ / shares				$ 1.11
Number of stock sold, value | $						204,391	$ 100,000		323,326	$ 153,893
Loss on extinguishment of debt | $														$ (81,738)
Warrants to purchase shares of common stock						1,734,524							1,734,524	1,734,524		1,734,524
Stock-based compensation | $														$ 791,256	878,065
Expense related to warrants issued and outstanding | $															1,446,094
Expected Volatility [Member] | Minimum [Member]
Warrant measurement inputs						313							313	313		313
Expected Volatility [Member] | Maximum [Member]
Warrant measurement inputs						361							361	361		361
Risk-Free Interest [Member] | Minimum [Member]
Warrant measurement inputs						2.30							2.30	2.30		2.30
Risk-Free Interest [Member] | Maximum [Member]
Warrant measurement inputs						1.51							1.51	1.51		1.51
Detachable Warrant [Member]
Warrants to purchase shares of common stock						80,000							80,000	80,000		80,000
Warrant to purchase of common stock, value | $						$ 34,609							$ 34,609	$ 34,609		$ 34,609
Warrants,strike price per share | $ / shares						$ 1							$ 1	$ 1		$ 1
Warrant [Member]
Warrants to purchase shares of common stock						270,000							270,000	270,000		270,000
Warrant to purchase of common stock, value | $						$ 300,770							$ 300,770	$ 300,770		$ 300,770
Warrant expense recognized | $														$ 117,144
Cancellation of warrants to purchase common stock														333,000			90,000
Stock-based compensation | $														$ 791,257	$ 878,065
Expense related to warrants issued and outstanding | $														$ 650,000
Warrant [Member] | Minimum [Member]
Warrants,strike price per share | $ / shares						$ 0.30			$ 0.33				$ 0.30	$ 0.30	$ 0.33	$ 0.30
Warrant [Member] | Maximum [Member]
Warrants,strike price per share | $ / shares						$ 3.89			$ 3.89				$ 3.89	$ 3.89	$ 3.89	$ 3.89
Common Stock [Member]
Number of shares issued						270,000	77,700				904,759
Number of shaes issued for compensaton						90,000	30,300			24,384
Number of shaes issued for compensaton, value | $						$ 100				$ 27
Number of stock sold						486,000	360,000		22,500	277,008
Number of stock sold, value | $						$ 540	$ 400		$ 25	$ 308
Cancellation of warrants to purchase common stock														333,000
Warrant One [Member]
Cancellation of warrants to purchase common stock														54,000
Warrant Two [Member]
Warrants to purchase shares of common stock						9,000							9,000	9,000		9,000
Warrant to purchase of common stock, value | $						$ 6,800							$ 6,800	$ 6,800		$ 6,800
Cancellation of warrants to purchase common stock														6,800
Accrued Expenses - Related Party [Member]
Reduction in accrued compensation | $														$ 375,936
Accounts Payable and Accrued Expenses [Member]
Reduction in accrued compensation | $														$ 80,029
One Share of Common Stock and 1/2 Warrant Share [Member]
Number of stock sold														160,000
Number of stock sold, value | $														$ 104,000
Sale of stock price per share | $ / shares						$ 0.65							$ 0.65	$ 0.65		$ 0.65
Warrants to purchase shares of common stock						69,391							69,391	69,391		69,391
John Lai [Member]
Retention of escrowed shares			600,000
Warrants to purchase shares of common stock						540,000							540,000	540,000		540,000
Warrant to purchase of common stock, value | $						$ 299,973							$ 299,973	$ 299,973		$ 299,973
Shares exercisable term														5 years
Warrants,strike price per share | $ / shares						$ 0.56							$ 0.56	$ 0.56		$ 0.56
John Lai [Member] | Warrants One [Member]
Warrants to purchase shares of common stock						79,397							79,397	79,397		79,397
Warrant to purchase of common stock, value | $						$ 38,744							$ 38,744	$ 38,744		$ 38,744
Shares exercisable term														5 years
Warrants,strike price per share | $ / shares						$ 0.50							$ 0.50	$ 0.50		$ 0.50
John Lai [Member] | Vest Upon Performance-Based Milestone [Member]
Number of shares vested														180,000
John Lai [Member] | Vest Quarterly Over Three Years [Member] | October 1, 2019 [Member]
Number of shares vested														360,000
Randall Meyer [Member]
Warrants to purchase shares of common stock						4,852							4,852	4,852		4,852
Warrant to purchase of common stock, value | $						$ 2,368							$ 2,368	$ 2,368		$ 2,368
John Dolan [Member]
Warrants to purchase shares of common stock						220,500							220,500	220,500		220,500
Warrant to purchase of common stock, value | $						$ 122,489							$ 122,489	$ 122,489		$ 122,489
Number of shares vested			40,500
Shares exercisable term			5 years
Warrants,strike price per share | $ / shares						$ 0.56							$ 0.56	$ 0.56		$ 0.56
John Dolan [Member] | Warrants One [Member]
Warrants to purchase shares of common stock						15,880							15,880	15,880		15,880
Warrant to purchase of common stock, value | $						$ 7,749							$ 7,749	$ 7,749		$ 7,749
Shares exercisable term														5 years
Warrants,strike price per share | $ / shares						$ 0.50							$ 0.50	$ 0.50		$ 0.50
John Dolan [Member] | Granted as a Bonus [Member]
Warrants to purchase shares of common stock			40,500
John Dolan [Member] | Vest Upon Performance-Based Milestone [Member]
Number of shares vested			90,000
John Dolan [Member] | Vest Quarterly Over Three Years [Member] | October 1, 2019 [Member]
Number of shares vested			90,000
One Shareholder [Member]
Number of stock sold														360,000
Number of stock sold, value | $														$ 100,000
Sale of stock price per share | $ / shares						0.28							0.28	$ 0.28		$ 0.28
One Service Provider [Member]
Number of shares issued for services																270,000
Various Accredited Investors [Member]
Number of stock sold														486,000
Number of stock sold, value | $														$ 135,000
Sale of stock price per share | $ / shares						$ 0.28							$ 0.28	$ 0.28		$ 0.28
Investor Relations Services [Member] | Barry Kaplan Associates [Member] | Forecast [Member]
Number of shares issued for services												90,000
Management Team Members [Member]
Warrants to purchase shares of common stock						360,000							360,000	360,000		360,000
Warrant to purchase of common stock, value | $						$ 199,982							$ 199,982	$ 199,982		$ 199,982
Warrant expense recognized | $														$ 0
Three New Directors [Member]
Warrants to purchase shares of common stock						270,000							270,000	270,000		270,000
Warrant to purchase of common stock, value | $						$ 119,954							$ 119,954	$ 119,954		$ 119,954
Three New Directors [Member] | August 2020 and May 2021 [Member]
Number of shares vested													135,000
Shares exercisable term													5 years
Warrants,strike price per share | $ / shares						$ 0.33							$ 0.33	$ 0.33		$ 0.33
Scott Johnson [Member]
Warrants to purchase shares of common stock						4,852							4,852	4,852		4,852
Warrant to purchase of common stock, value | $						$ 2,368							$ 2,368	$ 2,368		$ 2,368
Number of shares vested														135,000
Gregory Cash [Member]
Warrants to purchase shares of common stock						7,059							7,059	7,059		7,059
Warrant to purchase of common stock, value | $						$ 3,445							$ 3,445	$ 3,445		$ 3,445
Number of shares vested														135,000
James Martin [Member]
Warrants to purchase shares of common stock						4,412							4,412	4,412		4,412
Warrant to purchase of common stock, value | $						$ 2,153							$ 2,153	$ 2,153		$ 2,153
Number of shares vested														135,000
John Carruth [Member]
Warrants to purchase shares of common stock						450,000							450,000	450,000		450,000
Warrant to purchase of common stock, value | $						$ 249,997							$ 249,997	$ 249,997		$ 249,997
Shares exercisable term														5 years
Warrants,strike price per share | $ / shares						$ 0.56							$ 0.56	$ 0.56		$ 0.56
John Carruth [Member] | Vest Upon Performance-Based Milestone [Member]
Number of shares vested														90,000
John Carruth [Member] | Vest Quarterly Over Three Years [Member] | October 1, 2019 [Member]
Number of shares vested														360,000
David Deming [Member]
Warrants to purchase shares of common stock						41,250							41,250	41,250		41,250
Warrant to purchase of common stock, value | $						$ 22,915							$ 22,915	$ 22,915		$ 22,915
Shares exercisable term														5 years
Warrants,strike price per share | $ / shares						$ 0.49							$ 0.49	$ 0.49		$ 0.49
David Deming [Member] | Issued For Services [Member]
Warrants to purchase shares of common stock						4,412							4,412	4,412		4,412
Warrant to purchase of common stock, value | $						$ 2,153							$ 2,153	$ 2,153		$ 2,153
Accredited Investors [Member] | Detachable Warrant [Member]
Warrants to purchase shares of common stock						160,000							160,000	160,000		160,000
Warrant to purchase of common stock, value | $						$ 104,000							$ 104,000	$ 104,000		$ 104,000
Shares exercisable term														3 years
Warrants,strike price per share | $ / shares						$ 0.65							$ 0.65	$ 0.65		$ 0.65
Several Directors of the Company [Member]
Warrants,strike price per share | $ / shares						$ 0.49							$ 0.49	$ 0.49		$ 0.49
Robert Rudelius [Member]
Warrants to purchase shares of common stock						5,735							5,735	5,735		5,735
Warrant to purchase of common stock, value | $						$ 2,799							$ 2,799	$ 2,799		$ 2,799
Joseph Jasper [Member]
Warrants to purchase shares of common stock						3,528							3,528	3,528		3,528
Warrant to purchase of common stock, value | $						$ 1,722							$ 1,722	$ 1,722		$ 1,722
David Masters [Member]
Warrants to purchase shares of common stock						2,647							2,647	2,647		2,647
Warrant to purchase of common stock, value | $						$ 1,292							$ 1,292	$ 1,292		$ 1,292
Settlement Agreement [Member] | John Lai [Member]
Number of shaes issued for compensaton														347,500
Number of shaes issued for compensaton, value | $														$ 116,000
Shares holding term														3 years
Settlement Agreement [Member] | Randall Meyer [Member]
Number of shaes issued for compensaton														575,808
Number of shaes issued for compensaton, value | $														$ 191,936
Shares holding term														3 years
Settlement Agreement [Member] | John Dolan [Member]
Number of shaes issued for compensaton														204,000
Number of shaes issued for compensaton, value | $														$ 68,000
Shares holding term														3 years
Settlement Agreement [Member] | Former Employee [Member]
Number of shaes issued for compensaton														168,060
Number of shaes issued for compensaton, value | $														$ 80,029
Consulting Agreement [Member]
Number of shares issued for services	150,000
Shares issued price per share | $ / shares	$ 0.42
Shares issued for services during period, values | $	$ 70,500

Common Stock and Warrants - Sch

Common Stock and Warrants - Schedule of Warrant Activity (Details) - Warrant [Member] - $ / shares	9 Months Ended	12 Months Ended
	Dec. 31, 2019	Mar. 31, 2019
Number of Warrants, Outstanding, Beginning Balance	3,818,919	3,138,046
Number of Warrants, Granted	1,734,524	1,782,478
Number of Warrants, Exercised		999,925
Number of Warrants, Expired		11,680
Number of Warrants, Cancelled	333,000	90,000
Number of Warrants, Outstanding, Ending Balance	5,220,443	3,818,919
Weighted-Average Exercise Price, Outstanding, Beginning Balance	$ 0.55	$ 0.66
Weighted-Average Exercise Price, Granted	0.54	0.46
Weighted-Average Exercise Price, Exercised		0.40
Weighted-Average Exercise Price, Expired		0.33
Weighted-Average Exercise Price, Cancelled	0.48	1.11
Weighted-Average Exercise Price, Outstanding, Ending Balance	$ 0.54	$ 0.55
Warrants Exercisable, Outstanding, Beginning Balance	3,035,035	2,190,241
Warrants Exercisable, Granted
Warrants Exercisable, Exercised
Warrants Exercisable, Expired
Warrants Exercisable, Cancelled
Warrants Exercisable, Outstanding, Ending Balance	3,996,828	3,035,035
Weighted-Average Exercisable Price, Outstanding, Beginning Balance	$ 0.54	$ 0.63
Weighted-Average Exercisable Price, Granted
Weighted-Average Exercisable Price, Exercised
Weighted-Average Exercisable Price, Expired
Weighted-Average Exercisable Price, Cancelled
Weighted-Average Exercisable Price, Outstanding, Ending Balance	$ 0.53	$ 0.54

Common Stock and Warrants - S_2

Common Stock and Warrants - Schedule of Range of Warrant Prices (Details) - Warrant [Member]	9 Months Ended
	Dec. 31, 2019$ / sharesshares
Number of Warrants, Outstanding | shares	5,220,443
Weighted-Average Exercise Price, outstanding	$ 0.54
Weighted-Average Remaining Contractual Life (Years), Outstanding	4 years 4 days
Number of Warrants, Exercisable | shares	3,996,828
Weighted-Average Exercise Price, Exercisable	$ 0.53
Range One [Member]
Range of Warrant Exercise Price, Lower limit	0.30
Range of Warrant Exercise Price, Upper limit	$ 0.50
Number of Warrants, Outstanding | shares	2,466,025
Weighted-Average Exercise Price, outstanding	$ 0.33
Weighted-Average Remaining Contractual Life (Years), Outstanding	5 years 4 days
Number of Warrants, Exercisable | shares	2,473,900
Weighted-Average Exercise Price, Exercisable	$ 0.33
Range Two [Member]
Range of Warrant Exercise Price, Lower limit	0.51
Range of Warrant Exercise Price, Upper limit	$ 1
Number of Warrants, Outstanding | shares	2,195,739
Weighted-Average Exercise Price, outstanding	$ 0.57
Weighted-Average Remaining Contractual Life (Years), Outstanding	3 years 2 months 27 days
Number of Warrants, Exercisable | shares	1,063,249
Weighted-Average Exercise Price, Exercisable	$ 0.59
Range Three [Member]
Range of Warrant Exercise Price, Lower limit	1.01
Range of Warrant Exercise Price, Upper limit	$ 4
Number of Warrants, Outstanding | shares	558,679
Weighted-Average Exercise Price, outstanding	$ 1.39
Weighted-Average Remaining Contractual Life (Years), Outstanding	2 years 7 months 24 days
Number of Warrants, Exercisable | shares	459,679
Weighted-Average Exercise Price, Exercisable	$ 1.44

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - $ / shares	1 Months Ended	3 Months Ended			9 Months Ended
	Jan. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2018	Dec. 31, 2019
Stock issued during period, shares					2,610,120
Number of securities called by warrants		1,734,524			1,734,524
Common Stock [Member]
Stock issued during period, shares		270,000	77,700	904,759
John Lai [Member]
Number of securities called by warrants		540,000			540,000
Warrants strike price per share		$ 0.56			$ 0.56
Subsequent Event [Member] | Accredited Investors [Member]
Stock issued during period, shares	160,000
Subsequent Event [Member] | Former Director [Member]
Stock issued during period, shares	63,141
Number of securities called by warrants	168,750
Warrants strike price per share	$ 0.30
Shares of common stock issued on cashless basis	63,141
Subsequent Event [Member] | John Lai [Member]
Warrants strike price per share	$ 0.33
Number of warrants, converted during period	168,750
Subsequent Event [Member] | John Lai [Member] | Common Stock [Member] | Cashless Conversion Provision {Member]
Shares converted during period	61,396
Subsequent Event [Member] | Agreement with Launchpad IR [Member]
Stock issued during period, shares	150,000